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Abstract 
OBJECTIVE: The objective of this selective Evidence Based Medicine (EBM) review is to 
determine if the use of probiotics can prevent the incidence of antibiotic-associated diarrhea 
(AAD) in adults using one or more antibiotics. 
STUDY DESIGN: Systematic review of three randomized, double-blind, placebo controlled 
trials in the English language published between 2013 and 2014. 
DATA SOURCES: Data sources obtained for this review were articles published in peer-
reviewed journals found using PubMed and Cochrane databases. 
OUTCOME MEASURED: All three studies defined diarrhea as the passage of three or more 
loose stools in a 24-hour period. All the studies used the Bristol Stool Scale. Stool consistency 
and frequency was recorded by patients, relatives, or clinical staff. 
RESULTS: Three double-blind, placebo-controlled trials were included and analyzed in this 
review. None of the three studies showed a statistical significance in AAD between their control 
groups and the groups receiving probiotics. The Chatterjee et al. study had a p-value of 0.19 and 
a Numbers Needed to Treat (NNT) of -20.83, the Wright et al. study had a p-value of 0.729 and a 
NNT of 28.57, and the Allen et al. study had a p-value of 0.72 and a NNT of 250. 
CONCLUSION: The three double-blind, placebo-controlled trials analyzed in this review 
showed no benefit in the use of probiotics for the prevention of AAD when comparing the 
placebo groups and the probiotics groups. 
KEYWORDS: probiotics, antibiotic-associated diarrhea. 
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INTRODUCTION 
 The widespread use of antibiotics, whether warranted or not comes with the risk of a 
patient developing antibiotic-associated diarrhea. Antibiotics can reduce native bacteria in the 
gastrointestinal tract, regardless if the antibiotic is a beta lactam that disrupts cell walls, a 
macrolide that prevents ribosomal build-up, or a quinolone that causes DNA break down. The 
reduction of this symbiotic bacteria causes harm to the host in more ways than one. The 
reduction causes malabsorption of nutrients, it can also allow opportunistic bacteria that is 
normally maintained in controlled levels to multiply without limits. Both of these processes can 
cause a patient to develop loose stools, or further complicate the disease process.  
  The term probiotics means for life1 and it describes live organisms that are used to 
enhance or replenish the native gastrointestinal flora found in the small and large intestines of 
humans. Although there are many different types of probiotics, the three double-blind, placebo-
controlled trials reviewed in this paper all used a strain of lactobacillus. Two of the three double-
blind, placebo-controlled trials used lactobacillus as well as Bifidobacterium. Their selection was 
based on their local production capabilities. Two of the studies used a capsule to deliver the 
probiotic, the third study used a suspension.  
In 1906, French Pediatrician, Henry Tissier, recognized that children with diarrhea had a 
low number of bacteria with a Y-shaped morphology.2 He also found that this bifid bacterium 
were found in greater numbers in the stool of healthy children.2 This and similar discoveries 
around the turn of the 20th century by other scientists who concluded similar results was the 
beginning of the prophylactic use of probiotics. It was not long before the scientific community 
realized that good health was associated with appropriate numbers of symbiotic bacteria in the 
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gastrointestinal tract. The probiotics help maintain the healthy balance of organisms found in our 
small and large intestine. When these ratios are altered, there is possibility for illness. 
Diarrhea is defined as three or more loose or watery stools per day.3, 4, 5, 6 Two of the 
three double-blind, placebo-controlled trials used the Bristol Stool Scale (BSS)7 to define bowel 
movements with stool type 6 and type 7 as diarrhea. 3, 5 The third study did not use the Bristol 
Stool Scale and defined diarrhea as the passage of at least three or more watery or loose stools 
per day for at least two days. 4 
 One of the most researched pathogens causative of antibiotic-associated diarrhea is 
Colostrum difficile, or C. difficile. The bacterium C. difficile is a spore forming bacteria that is 
identified in 15-25% of cases of antibiotic-associated diarrhea (AAD).6 In addition to AAD, the 
bacterium C. difficile can cause serious complications including toxic megacolon and even 
death.6 Most of these deaths are seen amongst patients 65 years old and older.8 In 2011 alone 
453,000 were diagnosed with a C. difficile infection and 29,300 died from complications.8 
  In the United States in 2009, 10.7 billion dollars were spent on antibiotic prescriptions.9 
Of those antibiotics prescribed, 30% were prescribed for infections that are self-limiting or viral 
infections.10 Antibiotic-associated diarrhea can occur whether the antibiotic is warranted or not. 
When antibiotics are given for self-limited or viral infections, it increases the number of times 
that providers may need to provide treatment for AAD and its complications. These nosocomial 
complications are not covered by insurance companies and government programs. This puts an 
unnecessary and costly burden on providers in all healthcare settings, as well as potentially 
damage the delicate provider-patient relationship. 
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The possibility of loss of income and patients has incentivized the medical field to look 
for preventative measures to avoid antibiotic-associated diarrhea. One of those measures is the 
use of probiotics as prophylactics for the prevention of AAD. This market had 36.6 billion 
dollars in global sales in 2015,11 and is expected to almost double in just 5 years.11 Other 
measures used to prevent or treat AAD is increased hydration, broad-spectrum antibiotics, and 
anti-diarrheal medications. 
It is known that antibiotics lower the number of native bacteria in the gastrointestinal 
tract.6 There has been limited older research that have provided a statistical significance in the 
use of probiotics for the prevention of AAD. However, it is also known that bacteria are ever 
evolving,6 and continuous research is needed to prove or disprove the current efficacy of 
probiotics. More research is needed to determine exactly what mechanisms probiotics use to help 
combat AAD. There also needs to be more research to differentiate if there is a higher rate of 
AAD with the usage of multiple antibiotics at the same time versus only one antibiotic. Lastly, it 
is not known if there are any long-term effects from short-term or chronic consumption of 
probiotics. The study done by Chatterjee et al. made mention of participants being withdrawn 
from the study if an adverse effect was noted but it did not state if the medication that caused the 
adverse effect was a probiotic or an antibiotic. The study by Allen et al. also withdrew patients 
based on adverse reactions, however the study states that the withdrawal was done to reduce the 
number of medications that the patients were taking rather than due to concerns of the safety of 
the probiotics. It is worth noting that the Allen et al. study had an exclusion criterion for potential 
participants that had previously had a reaction to probiotics, however it doesn’t provide details of 
what those adverse reactions were. 
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 In the current healthcare setting, the use of probiotics for the prevention and treatment of 
antibiotic-associated diarrhea is done with no clear preference in type or number of probiotic. It 
is based mainly on preference of the patient or the provider, and the local availability. The wide 
availability, perceived safety, and relative low cost has made the use of probiotics a popular 
choice as patients attempt to avoid the use of more medication to fix the initial complication of 
medication use. 
OBJECTIVE 
 The objective of this selective Evidence Based Medicine (EBM) review is to determine if 
the use of probiotics can prevent the incidence of antibiotic-associated diarrhea in adults using 
one or more antibiotics. 
METHOD 
 The studies discussed in this review are three double-blind, placebo-controlled 
randomized trials. Inclusion criteria used for study selection included that the participants were 
all over 18 years old, they received at least one type of antibiotic, and that the trials was done as 
double-blind, placebo-controlled. The only intervention required for study selection of the trials 
was the use of at least one of the popular and widely available types of probiotics, lactobacilli or 
bifidobacterial probiotic. The trials selected included a comparison of the probiotics to a visually 
matched placebo. The purpose of the trials was to compare whether the probiotics could prevent 
AAD.  The inclusion criteria of the trials needed to include the description of diarrhea as at least 
three soft or watery stools per day. Studies were not excluded based on whether the Bristol Stool 
Scale was used, or the specific number of episodes of bowel movements per day. Also, this 
systematic review does not seek to ascertain if the use of probiotics reduced the number of days 
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with diarrhea or the amount of bowel movements per day. Lastly, no trial was excluded based on 
which antibiotic was used, and no differentiation was made between antibiotics and their 
individual incidence of AAD.  
Research was done in both PubMed and Cochrane for the studies used. Keywords used 
for the articles were “probiotic” and “diarrhea.” The words “children”, “review”, 
“observational”, and “drink” were excluded to ensure that only pertinent trials were used. Also, 
to provide the most current data, only studies published in the last 5 years were used. Any study 
in a language other than English was excluded. To ensure the outmost rigor in the selection, only 
studies published in peer-review journals were utilized. The three studies were selected based on 
their relevance to the topic in question as well as the inclusion of patient oriented evidence that 
matters (POEMS). All the studies defined a statistically significant p-value of < 0.05. Specific 
inclusion and exclusion criteria, as well as demographic data are listed on table 1. 
Table 1 – Demographics and Characteristics of included studies 
Study Type #  
pts 
Ag
e 
Inclusion 
Criteria 
Exclusion 
Criteria 
W/
D 
Intervention
s 
Allen, et 
al. 
(2013) 
RCT 2941 71-
83.
5 
>65 years old, 
admitted to 
hospital, use 
of parenteral 
antibiotics 
within the last 
7 days or 
about to start 
Already had 
diarrhea, 
immunocompromis
ed, required 
intensive care, had 
a prosthetic heart 
valve, suffered 
from Colostrum 
difficile in the past 
3 months 
23 Two strains 
of 
lactobacilli 
and two 
strains of 
bifidobacter
ial or 
placebo 
were taken 
daily for 21 
days 
Chatterj
ee, et al. 
(2013) 
RCT 396 18-
70 
18 to 70 years 
old with 
prescription 
of a systemic 
oral antibiotic 
for seven days 
Had a course of 
systemic antibiotics 
in the last one 
month prior to 
screening, 
underlying 
53 L. 
acidophilus 
and 
Bifidobacter
ium or 
placebo 
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Gastrointestinal 
disease such as 
ulcerative colitis, 
crohn’s disease, 
malabsorption, GI 
bleeding, etc. 
were taken 
for 14 days 
Wright, 
et al. 
(2015) 
RCT 87 66-
10
1 
>65 years old 
admitted the 
geriatric ward 
Recent bowel 
surgery, artificial 
heart valve, 
rheumatic heart 
disease, infective 
endocarditis, 
intolerance or 
allergy to cow milk 
protein or citrus, 
artificial feeding, 
critical care, 
immunosuppression 
1 Yakult or 
placebo 
twice daily 
during 
admission 
 
OUTCOMES MEASURED 
 All the studies analyzed defined diarrhea as the passage of three or more loose or watery 
stools in a 24-hour period. Both the Chatterjee et al. study and the Wright et al. study required 
the diarrhea to be present for at least 2 consecutive days. Allen et al. did not specify a required 
length of time for diarrhea to be present. The study by Chatterjee et al. is the only study to not 
use the Bristol Stool Scale for accurate definition of stool samples. The study used the subjective 
terms ‘watery’ and ‘loose’ instead of an objective way of measurement. Both the Allen et al. 
study and the Wright et al. study used the Bristol Stool Scale type 6 or type 7 in their definition 
of diarrhea. The Allen et al. study also allowed participants of the study to describe diarrhea 
without the use of the Bristol Stool Scale. This was after the participants were discharged from 
inpatient care. Allen et al. used research nurses while the participants were admitted in the 
hospitals and phone interviews to assess the participants once they were discharged. Chatterjee et 
al. gave patients a diary for the patients to record their bowel movements. The diary was 
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reviewed at day 7 and at day 14. Wright et al. used the treatment teams to record the participant’s 
bowel movements. 
RESULTS 
 The Allen et al. study began with 2981 participants, of those participants 2941 completed 
the trial and were analyzed. There were many different reasons why 40 participants were 
excluded from the analysis. Reasons included participants being too unwell, being lost to follow 
up, participants declining, participants having diarrhea at recruitment, or being withdrawn by a 
relative. 1470 participants were placed in the probiotic group and 1471 participants were placed 
in the control group. The probiotic group was given a capsule containing the different probiotics 
once a day with food for 21 days. The control group was given a visually matched placebo once 
a day with food for 21 days. Both groups received the prescribed antibiotics daily based on the 
prescription criteria specific for each antibiotic. The study used research nurses to document the 
stool from each participant while the participants were in the hospital. After discharge, telephone 
interviews were used to document the findings from each participant. 159 participants developed 
AAD in the probiotic group, that is 10.8% of participants in that group. In the placebo group, 
10.4% of participants or 153 out of 1471 participants developed AAD. The p-value of the Allen 
et al. study was 0.72. With the use of dichotomous data, a RBI of 0.038 and an ABI of 0.004 
were calculated. This data was then used to calculate the NNT which was 250. These results are 
recorded in table 4. 
Table 4: Allen et al. - Probiotics vs placebo for prevention of AAD 
Study P-value RBI ABI NNT 
Allen et al. 0.72 0.038 0.004 250 
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P value considered significant if < 0.05 
The Chatterjee et al. study started with 396 participants and 343 participants completed 
the study. 44 participants were lost to follow up and 13 were withdrawn because they deviated 
from the protocols.  After withdrawals, 176 participants were in the probiotic group, and 167 
participants were in the placebo group. The probiotic group was given 2 capsules twice daily for 
14 days. The control group was given identical looking placebo capsules twice a day for 14 days. 
Both groups received the prescribed antibiotics daily based on the prescription criteria specific 
for each antibiotic. Both groups received a diary used to record the number of stools per day, the 
consistency, and color of stool, in addition to any other symptoms. The diary was reviewed at 
day 7 and at day 14. 19 participants developed AAD in the probiotic group, that is 10.8% of 
participants in that group. In the placebo group, 15.56% of participants or 26 out of 167 
participants developed AAD. Even though the probiotic group had a smaller incidence of AAD, 
it is not statistically significant. The p-value for the Chatterjee study is 0.191. With the use of 
dichotomous data, a RBI of -0.308 and an ABI of -0.048 were calculated. This data enabled us to 
calculate the NNT of -20.83. These results are recorded in table 2. 
Table 2: Chatterjee et al. study – Probiotics vs placebo for prevention of AAD 
Study P-value RBI ABI NNT 
Chatterjee et 
al. 
0.191 -0.308 -0.048 -20.83 
P value considered significant if < 0.05 
 The Wright et al. study started with 87 participants and 86 participants completed the 
study. 1 participant was withdrawn from the study because the participant’s family had 
administered probiotics to the participant after the study had commenced, however the patient 
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was included in the statistical analyzes. 41 participants were placed in the probiotic group, and 
46 participants were placed in the placebo group. The participants in the probiotic group received 
65 milliliters bottles twice a day during the length of their admissions into the hospital (average 
length of admission was 24 days). The control group was given a visually matched placebo for 
the duration of their hospital stay (average consumption was 22 days). Both groups received the 
prescribed antibiotics daily based on the prescription criteria specific for each antibiotic. The 
treatment team used the Bristol Stool Scale to record the findings for both the placebo and the 
probiotic group. 5 participants in the probiotic group developed AAD. In the control group, 4 
participants developed AAD. That is a 12% and 9% development of AAD, respectively. The p-
value for this study was 0.729. With the use of dichotomous data, a RBI of 0.402 and an ABI of 
0.035 were calculated. This data was used to calculate the NNT of 28.57. These results are 
recorded in table 3. 
Table 3: Wright et al. - Probiotics vs placebo for prevention of AAD 
Study P-value RBI ABI NNT 
Wright et al. 0.729 0.402 0.035 28.57 
P value considered significant if < 0.05 
DISCUSSION 
The purpose of this systematic analysis of the studies was to determine if the use of 
popular and readily available probiotics is a safe alternative for the prevention of antibiotic-
associated diarrhea in adults that use one or more antibiotics to treat bacterial infections. AAD is 
a very common side effect of the wide-spread use of antibiotics. While analyzing these studies it 
was calculated that among all participants, 11.41% developed antibiotic-associated diarrhea. 
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That 11.41% of participants is regardless of what antibiotic was used, which type of probiotic 
was used, or whether the participant received probiotics versus a visually-matched placebo. This 
high incidence rate is the reason why many people look for safer ways to preventing the 
development of diarrhea. 
 Only one study specifically mentioned the potential side effects of probiotic use. 
Chatteerje et al. had participants document any adverse effects during their time in the trial. 2% 
of the participants in the probiotic group mention adverse effects. There was no mention of 
adverse effects reported in the control group. The adverse effects reported by participants were 
epigastric discomfort, abdominal pain, belching, and dyspepsia. Probiotics are mainly labeled as 
dietary supplements, which means that they are not extensively regulated by government 
agencies,12 this makes the reporting of side effect very minimal. 
The three studies concluded that the use of probiotics does not work as a prophylactic for 
the prevention of antibiotic-associated diarrhea. Of these studies, the study by Allen et al. 
showed a NNT of 250, meaning one out of every 250 patients would benefit from the use of 
probiotics to prevent antibiotic-associate diarrhea. The third study, by Chatterjee et al. had 
almost a 5% reduction of antibiotic-associated diarrhea in the probiotic group when compared to 
the control group. However, this reduction was not statistically significant. 
CONCLUSIONS 
 After the analyzation of the three placebo-controlled double-blind trials, the use of 
probiotics for the prevention of antibiotic-associated diarrhea has not shown a statistically 
significant difference when compared to control groups. The Allen et al. study, being the largest 
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and with an NNT of 250 shows that there is no clinical or economic advantage for the use or 
recommendation of probiotics. 
Further analysis may be necessary to evaluate whether different antibiotic regimens 
would benefit from probiotic use. Other areas open for analysis would be whether one type of 
probiotic is superior to another or whether a higher dosage of probiotic would prove more 
beneficial. An example of a possible future trial would be a study of specifically the use of 
lactobacillus in the prevention of antibiotic-associated diarrhea in patients taking a beta lactam. 
The studies analyzed in this paper all choose the probiotics based on their local availability. 
There is great momentum within the probiotic industry. The probiotic market is a multibillion-
dollar global industry. Probiotics are easily accessible, and with the perception of a side-effect 
free profile, it is unlikely that their use will be slowed down. This momentum could be used to 
the advantage of scientists to run more specific trials to further expand our knowledge of their 
efficacy. However as per this review, the use of probiotics does not currently show enough 
statistical significance to be used in the prevention or treatment of antibiotic-associated diarrhea. 
 
 
REFERENCES 
1. Reid G, Morelli L, Gilliland SE. Joint FAO/WHO Expert Consultation on Evaluation of 
Health and Nutritional Properties of Probiotics in Food including Powder Milk with Live 
Lactic Acid Bacteria. Vol 85. Cordoba, Argentina: Food and Agriculture Organization of 
the United Nations; 2001. http://www.fao.org/3/a-a0512e.pdf. Accessed November 30, 
2017. 
 
2. Oyetayo VO, Oyetayo FL. Potential of probiotics as biotherapeutic agents targeting the 
innate immune system. African Journal of Biotechnology. 2005;4(2):123-127. 
https://tspace.library.utoronto.ca/bitstream/1807/6600/1/jb05023.pdf. Accessed 
November 30, 2017. 
 
3. Allen, S. J., Wareham, K., Wang, D., Bradley, C., Sewell, B., Hutchings, H. Phillips, C. 
J. (2013). A high-dose preparation of lactobacilli and bifidobacteria in the prevention of 
antibiotic-associated and Clostridium difficile diarrhoea in older people admitted to 
hospital: a multicentre, randomised, double-blind, placebo-controlled, parallel arm trial 
(PLACIDE). Health Technology Assessment (Winchester, England), 17(57), 1–140. 
http://doi.org/10.3310/hta17570 
 
4. Chatterjee, S., Kar, P., Das, T., Ray, S., Gangulyt, S., Rajendiran, C., et al. (2013). 
Randomised placebo-controlled double blind multicentric trial on efficacy and safety of 
lactobacillus acidophilus LA-5 and bifidobacterium BB-12 for prevention of antibiotic-
associated diarrhoea. The Journal of the Association of Physicians of India, 61(10), 708-
712. 
 
5. Wright, K., Wright, H., & Murray, M. (2015). Probiotic treatment for the prevention of 
antibiotic-associated diarrhoea in geriatric patients: A multicentre randomised controlled 
pilot study. Australasian Journal on Ageing, 34(1), 38-42. doi:10.1111/ajag.12116 
 
6. Papadakis MA, McPhee SJ, Rabow MW. Current medical diagnosis & treatment 2016. 
United States of America: McGraw Hill Education; 2016. 
 
7. Caroff DA, Edelstein PH, Hamilton K, Pegues DA. The Bristol Stool Scale and Its 
Relationship to Clostridium difficile Infection. Journal of Clinical Microbiology. 
2014;52(9):3437-3439. doi:10.1128/JCM.01303-14. 
 
8. Lessa FC, Mu Y, Bamberg WM, et al. Burden of Clostridium difficile Infection in the 
United States. New England Journal of Medicine. 2015;372(9):825-834. 
doi:10.1056/nejmoa1408913. 
 
9. Suda KJ, Hicks LA, Roberts RM, Hunkler RJ, Danziger LH. A national evaluation of 
antibiotic expenditures by healthcare setting in the United States, 2009. Journal of 
Antimicrobial Chemotherapy. 2012;68(3):715-718. doi:10.1093/jac/dks445. 
 
 
10. 1 in 3 antibiotic prescriptions unnecessary. Centers for Disease Control and Prevention. 
https://www.cdc.gov/media/releases/2016/p0503-unnecessary-prescriptions.html. 
Published May 3, 2016. Accessed November 30, 2017. 
 
11. Probiotics Market Size By End Use (Human, Animal), By Application (Functional Foods 
& Beverages [Dairy, Non-dairy, Cereals, Baked Goods, Fermented Meat Products, Dry 
Foods], Dietary Supplements [Food, Nutritional, Specialty, Infant Formula], Animal Feed 
Probiotics), Industry Analysis Report, Regional Outlook (U.S., Germany, UK, China, 
Japan, India, Brazil), Application Potential, Price Trends, Competitive Market Share & 
Forecast, 2017 – 2024. Probiotics Market Growth - Industry Size, Share Report 2017-
2024. https://www.gminsights.com/industry-analysis/probiotics-market. Published 
September 2017. Accessed November 30, 2017. 
 
12. Degnan FH. The US Food and Drug Administration and Probiotics: Regulatory 
Categorization. Clinical Infectious Diseases. 2008;46(Supplement_2): S133-S136. 
doi:10.1086/523324. 
